Patents Assigned to Silver Creek Pharmaceuticals, Inc.
  • Bi-Specific Fusion Proteins
    Publication number: 20240101713
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: October 9, 2023
    Publication date: March 28, 2024
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof
    Patent number: 11879002
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: January 23, 2024
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Bi-specific fusion proteins
    Patent number: 11814443
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 14, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20230322951
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 12, 2023
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 11673970
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • METHODS OF TREATING SKIN TISSUE DAMAGE
    Publication number: 20220162283
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Application
    Filed: February 10, 2022
    Publication date: May 26, 2022
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D.J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5
    Patent number: 11155593
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: October 26, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Bi-specific fusion proteins
    Patent number: 10988547
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: April 27, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10858450
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5
    Patent number: 10633425
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Bi-specific fusion proteins
    Patent number: 10407512
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
    Patent number: 10040840
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 7, 2018
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang